Your browser doesn't support javascript.
loading
Reimbursed Medication Adherence Enhancing Interventions in European Countries: Results of the EUREcA Study.
Ágh, Tamás; Hadziabdic, Maja Ortner; Garuoliene, Kristina; Granas, Anne Gerd; Aarnio, Emma; Menditto, Enrica; Gregório, João; Barnestein-Fonseca, Pilar; Mevsim, Vildan; Kardas, Przemyslaw.
Afiliación
  • Ágh T; Syreon Research Institute, Budapest, Hungary.
  • Hadziabdic MO; Center for Health Technology Assessment and Pharmacoeconomic Research, University of Pécs, Pécs, Hungary.
  • Garuoliene K; Centre for Applied Pharmacy, Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia.
  • Granas AG; Pharmacy Center, Institute of Biomedical Science, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
  • Aarnio E; Section for Pharmaceutics and Social Pharmacy, Department of Pharmacy, University of Oslo, Oslo, Norway.
  • Menditto E; Norwegian Centre for E-health Research, University Hospital of North Norway, Tromsø, Norway.
  • Gregório J; School of Pharmacy, University of Eastern Finland, Kuopio, Finland.
  • Barnestein-Fonseca P; CIRFF, Center of Pharmacoeconomics and Drug Utilization Research, Department of Pharmacy University of Naples Federico II, Naples, Italy.
  • Mevsim V; CBIOS, Universidade Lusófona's Research Center for Biosciences & Health Technologies, Lisboa, Portugal.
  • Kardas P; CUDECA Institute for Training and Research in Palliative Care, CUDECA Hospice Foundation, Málaga, Spain.
Front Pharmacol ; 13: 892240, 2022.
Article en En | MEDLINE | ID: mdl-35784711
Introduction: Current literature lacks detailed understanding of the reimbursement framework of medication adherence enhancing interventions (MAEIs). As part of the ENABLE COST Action, the EUREcA ("EUropen REimbursement strategies for interventions targeting medication Adherence") study aimed to provide an in-depth overview of reimbursed MAEIs currently available in European countries at national and regional levels and to pave the way for further MAEIs to be implemented in the future. Methods: A web-based, cross-sectional survey was performed across 38 European countries and Israel. The survey questionnaire was developed as a result of an iterative process of discussion informed by a desk review. The survey was performed among invited ENABLE collaborators from June to July 2021. Besides descriptive analysis, association between country income and health care expenditure, and the availability of reimbursed MAEIs were also assessed. Results: The survey identified 13 reimbursed MAEIs in nine countries: multi-dose drug dispensing (n = 5), medication review (n = 4), smart device (n = 2), mobile application (n = 1), and patient education (n = 1). The median GDP per capita of countries having ≥1 reimbursed MAEI was significantly higher compared to countries having no reimbursed adherence intervention (33,888 EUR vs 16,620 EUR, respectively; p = 0.05). Conclusions: Our findings highlight that to date only a small number of MAEIs have been reimbursed in European countries. Comprehensive health technology assessment recommendations and multi-stakeholder collaboration could help removing barriers related to the implementation and reimbursement of MAEIs.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Health_technology_assessment / Prognostic_studies / Qualitative_research / Risk_factors_studies Idioma: En Revista: Front Pharmacol Año: 2022 Tipo del documento: Article País de afiliación: Hungria Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Health_technology_assessment / Prognostic_studies / Qualitative_research / Risk_factors_studies Idioma: En Revista: Front Pharmacol Año: 2022 Tipo del documento: Article País de afiliación: Hungria Pais de publicación: Suiza